2012 to address the management of these infections in the local settings. Experts on infectious diseases in Taiwan convened and issued a guideline for the treatment of MRSA infections involving the skin and soft tissue, musculoskeletal, respiratory, cardiovascular, and central nervous systems.
Other important issues addressed in the symposium were the reporting of minimum inhibitory concentrations (MICs), the dosage, and therapeutic drug monitoring of vancomycin. Determination of vancomycin MIC was recommended in patients with complicated MRSA infections or treatment failure. Vancomycin dosages of 30e60 mg/kg of actual body weight per day given at an interval of 6e12 hours were recommended for patients with normal renal function. For seriously ill patients, including patients with bacteremia, sepsis, meningitis, osteomyelitis, pneumonia, and severe skin and soft tissue infections, a loading dose of 25e30 mg/kg (based on actual body weight) may be considered. Serum trough levels should be obtained just before the fourth or fifth dose and vancomycin dosage should be adjusted to attain trough serum vancomycin concentrations of 15e20 mg/mL when the vancomycin MIC is 1 mg/mL (Table 1) .
The guidelines were established based on the local epidemiology, susceptibility patterns of MRSA, and expert consensus. The guidelines were approved by the board members of the Infectious Disease Society of Taiwan (IDST). Free access to these guidelines is provided in the Journal of Immunology, Microbiology and Infection (www.ejmii.com and www.e-jmii.com) and the web site of IDST (http:// www.idsroc.org.tw/) to increase the access for medical practitioners in Taiwan. 
